Skip to main content
Carl Regillo, MD, Ophthalmology, Plymouth Meeting, PA

CarlDRegilloMD

Ophthalmology Plymouth Meeting, PA

Retinal Disease

Director, Wills Eye Retina Service

Dr. Regillo is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Regillo's full profile

Already have an account?

  • Office

    4060 Butler Pike
    Ste 200
    Plymouth Meeting, PA 19462
    Phone+1 800-331-6634
    Fax+1 267-420-1360

Summary

  • Dr. Carl D. Regillo is Professor of Ophthalmology at Thomas Jefferson University, Chief of the Retina Service of Wills Eye Hospital and Founder of the Wills Eye Clinical Retina Research Unit in Philadelphia. He received his medical degree from Harvard Medical School and performed his ophthalmology residency and vitreoretinal fellowship at Wills Eye Hospital. He has authored over 300 publications along with over 50 book chapters and 9 major books. He has been an investigator on numerous major clinical trials developing new medical and surgical treatments for retinal disorders such as macular degeneration and diabetic retinopathy. He is invited to lecture worldwide and serves on the scientific editorial board for several top ophthalmology peer-reviewed journals. As a recognized leader in the field, he is a recipient of the many local, national, and international awards including American Academy of Ophthalmology Achievement, Senior Achievement, Secretariat, and Lifetime Achievement Awards and the American Society of Retinal Specialists Honor, Senior Honor, Presidential, and Founders Awards. He was charter inductee of the Retina Hall of Fame and named in the Ophthalmologist Power List of the top 100 most influential ophthalmologists in the world. He was also listed among the top 150 ophthalmologists in the US by Newsweek.

Education & Training

  • Sidney Kimmel Medical College at Thomas Jefferson University/Wills Eye Hospital
    Sidney Kimmel Medical College at Thomas Jefferson University/Wills Eye HospitalFellowship, Surgical Retina and Vitreous, 1992 - 1994
  • Sidney Kimmel Medical College at Thomas Jefferson University/Wills Eye Hospital
    Sidney Kimmel Medical College at Thomas Jefferson University/Wills Eye HospitalResidency, Ophthalmology, 1989 - 1992
  • Brigham and Women's Hospital
    Brigham and Women's HospitalInternship, Internal Medicine, 1988 - 1989
  • Harvard Medical School
    Harvard Medical SchoolMD, 1984 - 1988
  • Harvard Medical School
    Harvard Medical SchoolClass of 1988
  • Northeastern University
    Northeastern UniversityBS, 1979 - 1984

Certifications & Licensure

  • NJ State Medical License
    NJ State Medical License 1998 - 2025
  • PA State Medical License
    PA State Medical License 1990 - 2024
  • CA State Medical License
    CA State Medical License 1994 - 1998
  • MA State Medical License
    MA State Medical License 1984 - 1988
  • American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

  • The Ophthalmologist Power List (Top 100 most influential people in the world of ophthalmology) The Ophthalmologist, 2018, 2020, 2022, 2024
  • Top 150 Ophthalmologists in the US Newsweek, 2022
  • America's Top Doctors Castle Connolly, 2007-2018
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.  
    Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM, Ophthalmology
  • Pegaptanib for neovascular age-related macular degeneration.  
    Gragoudas ES, Adamis AP, Cunningham ET, Jr, N Engl J Med
  • Safety results of two phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage.  
    Kupperman BD, Thomas EL, de Smet MD, Am J Ophthalmol
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • Anecortave acetate administered sub-tenon’s retrobulbar with and without Visudyne PDT in patients with subfoveal age-related macular degeneration (AMD)-Clinical safety...
    D’Amico DJ, Duker J, Regillo C, Schneebaum C, Beasley C, Invest Ophthalmol Vis Sci
  • Scleral buckling procedures decrease central retinal artery mean blood flow velocity.
    Regillo C, Sergott R, Brown G, Invest Ophthalmol Vis Sci
  • Repair of AIDS retinitis-related retinal detachments with vitrectomy and silicone oil.
    Regillo C, Vander J, Fischer D, Belmont J, Kleiner R, Invest Ophthalmol Vis Sci
  • Join now to see all

Lectures

  • Anti-VEGF therapy for CRVO and BRVO. 
    Newport Beach, CA
  • Neovascular AMD treatment update 2012. 
    Multiple locations
  • Phamacologic vitreolysis and future management of symptomatic vitreomacular adhesion. 
    A CME program by Retina Today and NRI. Aspen, CO
  • Join now to see all

Press Mentions

  • EyePoint Pharmaceuticals Doses First Patient in Phase 3 LUGANO Trial for Wet AMD Therapy Duravyu
    EyePoint Pharmaceuticals Doses First Patient in Phase 3 LUGANO Trial for Wet AMD Therapy DuravyuOctober 24th, 2024
  • Adverum Biotechnologies Presents Positive End of Study Results from the OPTIC Trial in Wet AMD Including Two-Year Outcomes Following a Single Intravitreal Injection of Ixo-Vec (ADVM-022)
    Adverum Biotechnologies Presents Positive End of Study Results from the OPTIC Trial in Wet AMD Including Two-Year Outcomes Following a Single Intravitreal Injection of Ixo-Vec (ADVM-022)November 5th, 2022
  • Kodiak's Eylea Rival Hits 'Major Disappointment' with Failure in First of 6 Phase 3 Studies
    Kodiak's Eylea Rival Hits 'Major Disappointment' with Failure in First of 6 Phase 3 StudiesFebruary 23rd, 2022
  • Join now to see all

Professional Memberships